Aktieanalys

Lifecare: LFC-SEN-002 approvals in place - Redeye

Redeye Publicerad: 07 Nov 2023 12:38

Following today's approval from the NFSA, Lifecare has received all necessary approvals to commence the LFC-SEN-002 study, which aims to evaluate longevity and biocompatibility in dogs. In this study, the sensor will be tested for up to 90 days. We believe this marks another milestone for the company, not least for its veterinary subsidiary, Lifecare is working towards launching its first product in the veterinary market in mid-2024. Lifecare is scheduled to release its Q3 report next Tuesday (November 14), after which we will provide a more detailed take on the current outlook. Our base case remains at NOK4 for now.

Länk till analysen i sin helhet: https://www.redeye.se/research/955984/lifecare-lfc-sen-002-approvals-in-place?utm_source=finwire&utm_medium=RSS

Nyheter om Lifecare

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!